The contract manufacturer has 11 late-stage projects with commercial approval potential within the next few years, including a developer of GLP-1 therapeutics for obesity.
Three biomanufacturers are joining forces to spotlight how starting material quality drives scalability and consistency in cell and gene therapy production.
S-RACMO, a subsidiary of Tokyo-based Sumitomo Chemical Co., has completed its third facility and has plans for a fourth as demand for cell therapy CDMO services grows.
